NBC Securities Inc. Has $520,000 Stock Position in Progyny, Inc. (NASDAQ:PGNY)

NBC Securities Inc. grew its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 97,037.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 23,313 shares of the company's stock after purchasing an additional 23,289 shares during the period. NBC Securities Inc.'s holdings in Progyny were worth $520,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Voya Investment Management LLC boosted its stake in Progyny by 1.4% during the fourth quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock valued at $893,000 after buying an additional 701 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after buying an additional 1,355 shares during the last quarter. KBC Group NV lifted its holdings in shares of Progyny by 84.6% during the 4th quarter. KBC Group NV now owns 4,669 shares of the company's stock valued at $81,000 after buying an additional 2,140 shares during the last quarter. F M Investments LLC lifted its holdings in shares of Progyny by 13.0% during the 4th quarter. F M Investments LLC now owns 20,420 shares of the company's stock valued at $352,000 after buying an additional 2,342 shares during the last quarter. Finally, Entropy Technologies LP raised its stake in shares of Progyny by 5.5% in the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company's stock valued at $826,000 after acquiring an additional 2,499 shares in the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on PGNY. BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a research report on Monday, March 31st. Bank of America upped their price target on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group lowered their price target on Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Progyny has a consensus rating of "Hold" and a consensus target price of $23.45.

Progyny Stock Up 1.5%

Shares of PGNY traded up $0.32 during midday trading on Friday, reaching $21.68. 509,321 shares of the stock were exchanged, compared to its average volume of 1,706,096. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $30.42. The company has a market cap of $1.86 billion, a P/E ratio of 37.38, a PEG ratio of 2.39 and a beta of 1.37. The stock's 50 day simple moving average is $22.02 and its 200 day simple moving average is $20.35.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. During the same quarter in the previous year, the business posted $0.17 EPS. The firm's revenue for the quarter was up 16.5% on a year-over-year basis. As a group, analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.